贝伐珠单抗联合化疗对转移性结直肠癌患者血清EGFR及HER表达的影响研究

发布时间：2018-06-01 19:00

本文选题：受体 + 表皮生长因子　；参考：《重庆医学》2017年33期

【摘要】：目的探讨贝伐珠单抗联合化疗对转移性结直肠癌患者血清表皮生长因子受体(EGFR)及人表皮及不良反应生长因子受体(HER)表达的影响。方法选取2013年1月至2016年10月在该院接受治疗的转移性结直肠癌患者60例为研究对象,分为试验组(贝伐珠单抗联合mFOLFOX-6化疗方案)和对照组(mFOLFOX-6化疗方案),每组30例。观察两组患者的疗效及不良反应,采用ELISA检测患者血清中HER、EGFR的水平。结果治疗后试验组患者治疗总有效率为53.33%,对照组33.33%,差异有统计学意义(P0.05)。治疗后两组患者血清中HER和EGFR水平均有不同程度的降低,试验组比对照组降低的更多,差异有统计学意义(P0.05)。两组患者不良反应发生率比较差异无统计学意义(P0.05)。结论贝伐珠单抗联合化疗对转移性结直肠癌患者有较好的疗效。
[Abstract]:Objective to investigate the effect of bevacizumab combined with chemotherapy on the expression of serum epidermal growth factor receptor (EGFR) and human epidermal and adverse reaction growth factor receptor (hor) in patients with metastatic colorectal cancer. Methods 60 patients with metastatic colorectal cancer who were treated in our hospital from January 2013 to October 2016 were divided into trial group (bevacizumab combined with mFOLFOX-6 chemotherapy regimen) and control group (30 cases in each group). To observe the curative effect and adverse reaction of the two groups, and to detect the level of HER-EGFR in serum by ELISA. Results the total effective rate of treatment was 53.33 in the trial group and 33.33 in the control group. The difference was statistically significant (P 0.05). After treatment, the levels of HER and EGFR in serum of the two groups were decreased to some extent, and the levels of serum HER and EGFR in the experimental group were lower than those in the control group, and the difference was statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion bevacizumab combined with chemotherapy is effective in patients with metastatic colorectal cancer.
【作者单位】：江苏省江阴市人民医院肿瘤科;
【基金】：吴阶平医学基金会一般项目(320.6750.14197)
【分类号】：R735.3

【相似文献】